These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 26793895)

  • 1. [Role of chemotherapy in the treatment of castration resistant prostate cancer].
    Uemura H
    Nihon Rinsho; 2016 Jan; 74(1):143-8. PubMed ID: 26793895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer.
    Martin SK; Pu H; Penticuff JC; Cao Z; Horbinski C; Kyprianou N
    Cancer Res; 2016 Feb; 76(4):912-26. PubMed ID: 26645563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Association of Docetaxel Side Effects and Introduction of Subsequent Cabazitaxel for Castration-Resistant Prostate Cancer : A Clinical Study].
    Kujime Y; Sato M; Maekawa T; Umeda S; Matsushita M; Tei N; Miyake O
    Hinyokika Kiyo; 2024 Jun; 70(6):141-147. PubMed ID: 38967025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer.
    Lohiya V; Aragon-Ching JB; Sonpavde G
    Clin Med Insights Oncol; 2016; 10(Suppl 1):57-66. PubMed ID: 27773999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of the influence of GOLGA8B on prostate cancer progression and the resistance of castration-resistant prostate cancer to cabazitaxel.
    Li H; Wang X; Zhai M; Xu C; Chen X
    Discov Oncol; 2024 May; 15(1):152. PubMed ID: 38730195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer.
    Akaza H; Uemura H; Tsukamoto T; Ozono S; Ogawa O; Sakai H; Oya M; Namiki M; Fukasawa S; Yamaguchi A; Uemura H; Ohashi Y; Maeda H; Saito A; Takeda K; Naito S
    Int J Clin Oncol; 2016 Aug; 21(4):773-782. PubMed ID: 26793974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of taxanes in advanced prostate cancer.
    Cassinello J; Carballido Rodríguez J; Antón Aparicio L
    Clin Transl Oncol; 2016 Oct; 18(10):972-80. PubMed ID: 26856599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.
    Nussbaum N; George DJ; Abernethy AP; Dolan CM; Oestreicher N; Flanders S; Dorff TB
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):111-21. PubMed ID: 26832363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen : Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel].
    Thomas C; Bögemann M; König F; Machtens S; Schostak M; Steuber T; Heidenreich A
    Urologe A; 2016 Jun; 55(6):772-82. PubMed ID: 26820660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.
    Zafeiriou Z; Jayaram A; Sharp A; de Bono JS
    Drugs; 2016 Mar; 76(4):421-30. PubMed ID: 26873496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
    Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
    Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
    J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients.
    Mellado B; Jimenez N; Marin-Aguilera M; Reig O
    Clin Genitourin Cancer; 2016 Aug; 14(4):265-70. PubMed ID: 26827258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of Resistance in Antihormone Therapies of Advanced Prostate Cancer].
    Thelen P; Gschwend J; Wolff JM; Miller K
    Aktuelle Urol; 2016 Feb; 47(1):79-85. PubMed ID: 26814975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer.
    Takeuchi T; Okuno Y; Hattori-Kato M; Zaitsu M; Mikami K
    Res Rep Urol; 2016; 8():21-5. PubMed ID: 26870716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
    Morris MJ; Rathkopf DE; Novotny W; Gibbons JA; Peterson AC; Khondker Z; Ouatas T; Scher HI; Fleming MT
    Clin Cancer Res; 2016 Aug; 22(15):3774-81. PubMed ID: 26858312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
    Teply BA; Luber B; Denmeade SR; Antonarakis ES
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):72-8. PubMed ID: 26857146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.